• Like

The Point of Care Diagnostics Market 2014-2024

  • 724 views
Uploaded on

 

More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
724
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
41
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The Point of Care Diagnostics Market Forecast 2014-2024 Future Prospects for Leading Companies ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
  • 2. www.visiongain.com Contents 1.1 The Point of Care (POC) Diagnostics Market Highlights 1.2 Chapter Outlines 1.2.1 Aims, Scope and Format of the Report 1.3 Research and Analysis Methods 2.1 What are In Vitro Diagnostic (IVD) Tests? 2.2 Classifying In Vitro Diagnostics 2.2.1 FDA Classifications 2.2.2 IVD Classification in Australia 2.2.3 EDMA Classification 2.2.3.1 Clinical Chemistry: Not To Be Discounted 2.2.3.2 Immunochemistry 2.2.3.3 Haematology 2.2.3.4 Microbiology 2.2.3.5 Genetic Testing 2.2.3.6 Point Of Care Diagnostics: The Most Prominent Type 2.3 Diagnostics Regulation of the IVD and POC Market 2.3.1 FDA and CLIA Regulation of IVD and POC Tests 2.3.2 Regulation of IVD/POC Diagnostics in the EU: The EC (European Commission) Classification 2.4 Regulation for In-Vitro Diagnostics and POC Diagnostics 1. Report Overview 2. Introduction to In-Vitro Diagnostics and POC Diagnostics
  • 3. www.visiongain.com Contents 2.4.1 Top Ten Challenges in Regulation for In-Vitro Diagnostics 2.4.2 Device Excise Tax: A Threat to the Diagnostics Manufacturers 2.5 Uses of Point of Care (POC) Diagnostics 2.6 Advantages and Disadvantages of POC Diagnostics 3.1 Scope of this Report 3.2 Point of Care Diagnostics in the IVD Market, 2013 3.3 The World Point of Care Diagnostics Market in 2013 3.3.1 Self Testing Constituted the Largest Segment in the POC Market by the Point of Delivery 3.3.2 Point of Care Diagnostics Market Segmentation 3.4 The Global IVD Market: Sales Forecast, 2014-2024 3.4.1 Which Segments Will Drive the Global IVD Market in the Next 10 Years? 3.5 The Global Clinical Diagnostics Market Forecast, 2014-2024 3.6 The Global Point of Care Diagnostics Market: Sales Forecast 2014-2024 3.6.1 The Drive of Personalised Medicine 3.7 Market for POC Diagnostics Products: Leading Segments to 2024 3.7.1 Breakdown of the World Point of Care Diagnostics Main Submarkets: Changing Shares 2014-2024 3.7.2 Blood Glucose Testing Market Forecast 2014-2024 3.7.3 Infectious Diseases Testing Market Forecast 2014-2024 3.7.4 Rapid Coagulation Testing Market Forecast 2014-2024 3.7.5 Rapid Cardiac Marker Testing Market Forecast 2014-2024 3. The Point of Care Diagnostics Market, 2014-2024
  • 4. www.visiongain.com Contents 3.7.6 Cholesterol Testing Market Forecast 2014-2024 3.7.7 Pregnancy Testing Market Forecast 2014-2024 3.7.8 Other Segments Market Forecast 2014-2024 3.7.8.1 Cancer Diagnostics Will Be a Major Driver for This Segment 3.7.8.2 The Haematology Market Will Be Driven by Blood Gas Tests 3.7.8.3 A Recently Discovered Biomarker for Sepsis Can Set The Potential For A Future Rapid Blood Test 3.8 Scope of the Point of Care Diagnostics Market 3.9 Which Point of Care Diagnostic Segment Holds the Greatest Potential? 3.9.1 The Point of Care Diagnostics Market: Drivers and Restraints 2014-2024 4.1 Regional Breakdown of the World IVD Market: Sales Forecast by Country 2014-2024 4.2 Regional Breakdown of the World Point of Care Diagnostics Market in 2013 4.3 The World POC Diagnostics Market: Regional Forecasts 2014-2024 4.4 How Will Regional Market Shares Change to 2024? 4.5 The US POC Diagnostics Market, 2013 4.5.1 The US Will Still Dominate the POC Diagnostics Market in 2024 4.5.2 The US POC Diagnostics Market Forecast 2014 - 2024 4.5.3 Healthcare Expending in the US 4.5.4 The US POC Diagnostics Market: Drivers and Restraints 4.6 The Leading European POC Diagnostics Markets: Sales Forecasts 2014-2024 4.6.1 Variation in the European POCT Markets, 2014-2024 4.6.2 The German POC Diagnostics Market Forecast, 2014-2024 4. Leading National Point of Care Diagnostics Markets 2014-2024
  • 5. www.visiongain.com Contents 4.6.3 The UK POC Diagnostics Market Forecast 2014-2024 4.6.4 The French POC Diagnostics Market Forecast 2014-2024 4.6.5 The Italian POC Diagnostics Market Forecast 2014-2024 4.6.6 The Spanish POC Diagnostics Market Forecast 2014-2024 4.6.7 The Netherlands POC Diagnostics Market Forecast 2014-2024 4.6.8 The Belgian POC Diagnostics Market Forecast 2014-2024 4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024 4.7 The Japanese POC Diagnostics Market Forecast 2014-2024 4.7.1 The Japanese POC Diagnostics Market Overview 2014-2024 4.8 The BRICK Nations POC Diagnostics Market 4.8.1 The BRICK Nations POC Diagnostics Market: Overview 4.8.2 How Will BRICK Market Shares Change to 2024? 4.8.3 The BRICK Nations POC Diagnostics Market Forecast 2014-2014 4.8.3.1 The Chinese POCT Market Overview: Advances in China Lead to Expansion of the Market 4.8.3.1.1 The Chinese POC Diagnostics Market Forecast 2014-2024 4.8.3.2 The Indian POC Diagnostics Market Overview 4.8.3.2.1 The Indian POC Diagnostics Market Forecast 2014-2024 4.8.3.3 The South Korean POC Diagnostics Market Forecast 2014-2024 4.8.3.4 The Brazilian POC Diagnostics Market Forecast 2014-2024 4.8.3.5 The Russian POC Diagnostics Market Forecast 2014-2024 4.9 Rest of the World POC Diagnostics Markets Forecasts 2014-2024 4.9.1 Further Insights: Point of Care Diagnostics Approach for Developing Countries
  • 6. www.visiongain.com Contents 5.1 POC Blood Glucose Testing Market Overview 5.2 Global POC Blood Glucose Testing Market, 2013 5.3 POC Blood Glucose Testing Market Forecast 2014-2024 5.3.1 POC Blood Glucose Testing Market by Type of Meter 5.3.2 POC Blood Glucose Testing Market Segment by Components 5.3.2.1 POC Blood Glucose Testing Devices Currently Available in the Market, 2014 5.3.3 Leading Regional Markets in the POC Blood Glucose Testing Market, 2013 5.3.4 Leading Companies in the POC Blood Glucose Testing Market, 2014 5.3.4.1 Other Companies in the POC Blood Glucose Testing Market: Recent Advances 5.3.5 Market Prospects to 2024: Which Product Will Lead the Market? 5.3.5.1 Advantages and Disadvantages of the Current CGM Tests in the Market 5.4 Drivers and Restraints for the POC Blood Glucose Testing Market, 2014-2024 6.1 Global POC Coagulation Testing Market: Overview 6.2 Global POC Coagulation Testing Market in 2013 6.2.1 PT/INR Monitoring is the Largest Segment in the POC Coagulation Testing Market 6.3 Products Available in the POC Coagulation Testing Market, 2014 6.3.1 Patient Self Testing is a Fastest Growing Segment 6.4 POC Coagulation Testing Market Segment by Components 6.4.1 Test Strips Generate 85% of the Sales in the PT/INR POC Testing Market 6.5 POC Coagulation Testing Market by Type of Drug 5. Global Blood Glucose Testing Market, 2014-2024 6. Global Coagulation Testing Market, 2014-2024
  • 7. www.visiongain.com Contents 6.5.1 Anticoagulants 6.5.2 Heparins 6.5.3 Vitamin K Antagonists 6.5.4 Direct Thrombin Inhibitors 6.5.5 Direct Factor Xa Inhibitors 6.6 The POC Coagulation Testing Market by Regions, 2013 6.7 POC Coagulation Testing Market Forecast 2014-2024 6.8 Leading Companies in the POC Coagulation Testing Market, 2014 6.8.1 Roche Dominated the POC Coagulation Testing Market with CoaguChek XS System in 2013 6.8.2 Market Prospects to 2024: Who Will Be The Leading Product? 6.9 Drivers and Restraints for the POC Coagulation Testing Market, 2014-2024 7.1 Cardiac Marker Diagnostic Testing Market: Overview 7.1.1 The Majority of Cardiac Marker Testing is Conducted in Critical Care Settings 7.2 The Global Cardiac Marker Diagnostic Testing Market 2013 7.3 Cardiac Marker Diagnostic Testing Market Forecast 2014-2024 7.3.1 Leading Regional Markets in the Cardiac Marker Diagnostic Testing, 2013 7.3.1.1 Global Deaths Due to CVD in High, Middle and Low Income Countries, 2014 7.3.2 Leading Companies in the Cardiac Marker Diagnostic Testing Market, 2014 7.3.3 Cardiac Marker Diagnostic Tests Currently Under Development, 2014 7.3.3.1 cobas h232 Cardiac Marker (Roche) 7.3.3.2 QL Care Analyzer (CardioGenics) 7. Global Cardiac Marker Testing Market, 2014-2024
  • 8. www.visiongain.com Contents 7.3.3.3 Handheld Device (bioMerieux/Royal Philips Electronics) 7.3.4 Cardiac Marker Diagnostic Testing Market: Leading Products 7.3.5 Which Company is Dominating the Market? 7.3.6 A Leading Product: Abbott’s i-STAT 7.4 Drivers and Restraints for the Cardiac Marker Diagnostic Testing Market, 2014-2024 7.4.1 Challenges for the New Entrants in the Cardiac Markers Diagnostic Testing Market 8.1 POC Infectious Diseases Testing Market: Overview 8.2 Global POC Infectious Diseases Testing Market, 2013 8.2.1 Breakdown of the POC Infectious Diseases Testing Market by Diseases, 2013 8.2.1.1 Influenza/Flu 8.2.1.2 HIV 8.2.1.3 Hepatitis 8.2.1.4 Tuberculosis 8.2.1.5 Sexually Transmitted Diseases 8.3 The POC Infectious Diseases Testing Market: Leading Products 2014 8.3.1 HIV Leading POC Diagnostics Products, 2014 8.3.1.1 HIV Diagnostics Kits Approved by the FDA, 2014 8.3.2 The HIV Rapid Testing Market in the US, 2014 8.3.3 HIV POC Tests Pipeline, 2014 8.3.4 Driving Factors for Growth of HIV Rapid Testing: Past and Future 8.4 The Hepatitis POC Testing Market 8.4.1 First Rapid HCV Test Approved in the US 8. Global Infectious Diseases Testing Market, 2014-2024
  • 9. www.visiongain.com Contents 8.4.2 The Influenza POC Testing Market and Leading Companies, 2014 8.4.3 Driving Factors for Growth of Hepatitis Rapid Testing 8.4.4 POC Infectious Diseases Recent Trends 8.4.4.1 OraQuick Marker, OraSure Technologies: First OTC Home-Use Rapid HIV Test Approved by the FDA 8.4.4.2 Determine HIV-1/2 Ag/Ab Combo Test, Alere: First Rapid Diagnostic Test to Detect Both HIV-1 Antigen And HIV-1/2 Antibodies 8.4.5 Leading Regional Markets in the POC Infectious Diseases Testing 8.4.5.1 Infectious Diseases POC Testing: Regional Markets in 2013 8.5 Infectious Diseases POC Testing Market: Leading Companies 2014 8.6 The POC Infectious Diseases Testing Market Forecast, 2014-2024 8.7 Drivers and Restraints for the POC Infectious Diseases Testing Market, 2014-2024 9.1 The POC Pregnancy Testing Market: Overview 9.2 Global POC Pregnancy Testing Market, 2013 9.3 The POC Pregnancy Testing Market Forecast 2014-2024 9.3.1 The POC Pregnancy Testing Market: Leading Products 2014 9.3.2 Leading Companies in the POC Pregnancy Testing Market, 2014 9.4 Drivers and Restraints for the POC Pregnancy Testing Market, 2014-2024 10.1 Global POC Cholesterol Testing Market: Overview 10.2 The Global POC Cholesterol Testing Market in 2013 9. Global Pregnancy Testing Market, 2014-2024 10. Global Cholesterol Testing Market, 2014-2024
  • 10. www.visiongain.com Contents 10.3 The POC Cholesterol Testing Market Forecast 2014-2024 10.3.1 POC Cholesterol Testing Biomarkers: Overview 10.3.2 The POC Cholesterol Testing Market by Components 10.3.3 Recent Developments in the POC Cholesterol Testing Market, 2014 10.3.3.1 New Product 2014: Roche’s Accutrend Plus 10.3.4 POC Cholesterol Testing Market: Considerations in Production 10.4 Drivers and Restraints for the POC Cholesterol Testing Market, 2014-2024 11.1 Leadng POC Diagnostics Companies in 2014 11.2 Roche: Overview 11.2.1 Roche: Global Presence 11.2.2 Roche Diagnostics, 2014-2024 11.2.2.1 Roche Business Performance within the IVD Market, 2013 11.2.2.2 Roche Diagnostics Market Forecast 2014-2024 11.2.3 Roche Diagnostics: Key Launches Planned for 2014 11.2.4 Roche Diagnostics: POC Product Portfolio 11.2.5 Roche: Recent M&A Activity and Strategic Collaborations 11.3 Abbott: Continuously Transforming to Meet the Changing Needs 11.3.1 Abbott: Market Leader in the Coronary DES Sector 11.3.2 Abbott Diagnostics: Overview, 2013 11.3.2.1 Abbott Diagnostics: Leading Point-of-Care Platform 11.3.3 Abbott’s Fast Growing Diagnostics Division: Sales Forecast 2014-2024 11.3.4 Abbott Portfolio Sales and Recent Performance Analysis 11. Leading Companies in the POC Diagnostics Market, 2014
  • 11. www.visiongain.com Contents 11.3.5 Abbott: The i-STAT System 11.3.5.1 Recent M&A Activity and Strategic Collaborations 11.3.5.1.1 Abbott Laboratories Agreed to Acquire IDEV Technologies 11.3.5.1.2 Collaboration with Merck 11.3.5.2 Abbott IVD Segment: Strengths & Challenges 11.4 Siemens: A Highly Diversified Company 11.4.1 Siemens Healthcare: Prospects within the IVD Market 11.4.2 Siemens Healthcare: Sales Forecast 2014-2024 11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio 11.4.3.1 Siemens Healthcare Diagnostics Recent Trends, 2014 11.4.3.2 Recent M&A Activity and Strategic Collaborations 11.5 Alere Inc: A Strong Player 11.5.1 Alere Inc Performance Analysis in 2013 11.5.2 Alere Inc: Performance in Geographic Markets in 2013 11.5.3 Alere Inc.: Product Profile Overview 11.5.4 Alere’s Professional Diagnostics Market in 2013 11.5.5 Product Profile Recent Trends, 2014 11.5.6 Alere Market Forecast 2014-2024 11.5.7 Alere: Recent M&A Activity and Strategic Collaborations 11.6 Other Companies of Interest: Recent M&A Activity and Strategic Collaborations, 2014 12.1 Introduction 12.2 Drivers and Restraints for the POC Diagnostics Market 12. Qualitative Analysis of the POC Diagnostics Market, 2014-2024
  • 12. www.visiongain.com Contents 12.2.1 Commercial Drivers 12.2.2 Commercial Restraints 12.3 Strategic Review of the POC Diagnostics Market 12.4 Pestel Analysis 12.4.1 Political Factors 12.4.2 Economic Factors 12.4.3 Socio-Cultural Factors 12.4.4 Technological Factors 12.4.5 Environmental Factors 12.4.6 Legal Factors 12.5 P5F Analysis 12.5.1 Competitive Rivalry 12.5.2 Rivalry Among Competitors: [High] Diagnostics is a Promising Market 12.5.3 Potential Entrants into the POC Diagnostics Market 12.5.3.1 Threat of New Entrants: [Medium] Continuous Arousal of Innovations in the POCT Market 12.5.4 Who Are The Latent Substitutes? 12.5.5 Threat of Substitutes: [Medium]New Technologies Might Limit the Need to Monitor Diseases 12.5.6 Vertical Integration With Suppliers and Buyers 12.5.6.1 Power of Suppliers: [Medium] Increased Competition Outweigh Suppliers 12.5.6.2 Power of Buyers: [High] Demand and Health Systems Will Go Hand by Hand 12.6 SWOT Analysis and Strategies 12.6.1 Strengths: Timing is First
  • 13. www.visiongain.com Contents 12.6.2 Weaknesses: Awaiting Expanded Reimbursement Options 12.6.3 Opportunities: A Promising Market 12.6.4 Threats: Unmet Needs in the Low-Middle Income Countries 13.1 Interview with Dr. Terenzio Facchinetti, Director Business Development of UL Life and Health, UL International GmbH, Germany. 13.1.1 Impact of Remote Access on the POCT Market 13.1.2 UL’s Life and Health Business Unit: A Global Independent Safety Science Company 13.1.3 The Importance of Standardization and Regulations for the POC Market 13.1.4 Recommendations for the Future of POC Diagnostics: What to Expect 13.2 Interview with Dr. Keith Batchelder, CEO and Founder of Genomic Healthcare Strategies (GHS), USA. 13.2.1 Advantages of POC Diagnostics 13.2.2 Restraints of POC Diagnostics 13.2.3 About Genomic Healthcare Strategies 13.2.4 US has the Highest Potential for the POC Diagnostics Market 13.2.5 Remarkable Insights 13.3 Interview with Dr. David Huckle, President and CEO of Adams Business Associates (ABA), UK. 13.3.1 Remarkable Understanding on the POC Diagnostics Market 13.3.2 The Expert’s Perspective: Drivers and Restraints for POC Diagnostics 13.3.3 Recommendations for the Future POC Diagnostics Market 13.3.4 Further Insights from Dr. Huckle: Leading Companies 13. Expert Opinions
  • 14. www.visiongain.com Contents 13.4 Interview with Dr. Stéphan Cohen-Bacrie, Co-director of the Multi-site Laboratory of Immunohematology and Immunogenetics, French Blood Establishment, Burgundy- FrancheComté, France. 13.4.1 The French POC Diagnostics Market: Experienced Perspective 13.4.2 Restraints in the POC Diagnostics Market 13.4.3 The Advantage of Molecular Diagnostics 13.4.4 Innovations in Rural Africa: POC-labs 13.4.5 R&D in Focus: The Syndromic Panels and Microfluidics-based Methods 13.4.6 Where is the POC Diagnostics Market Heading?: An Expert’s View 14.1 Overview 14.2 The POC Testing in the IVD Market 14.3 The World POC Diagnostics Market Forecast 2014-2024 14.3.1 Leading Regional Markets Forecast 2014-2024 14.4 The World POC Diagnostics Market Forecast 2014-2024 14.5 POC Diagnostic Segments: Positions in the Market 2014 14.5.1 Current Advantages in POC Diagnostics 14.5.1.1 Comparison with Laboratory Testing 14.5.2 Leading POC Diagnostics Companies, 2014 14.6 Commercial Drivers for the Adoption of POC Tests 14.6.1 Commercial Restraints in the POC Diagnostics Market 14.7 Challenges for POC Diagnostics 14.8 The Future of the POC Diagnostics and Concluding Remarks 14. Conclusions
  • 15. www.visiongain.com Page 114 The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies diagnostics market. Furthermore international private hospitals and lab chains are acquiring private Belgian laboratories. Table 4.13 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn), AGR (%) and CAGR (%), 2013-2024 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Belgium ($bn) 0.15 0.15 0.16 0.17 0.17 0.18 0.19 0.20 0.21 0.22 0.24 0.25 AGR (%) 4.5 4.6 4.7 4.8 4.9 5.1 5.2 5.3 5.4 5.4 5.5 CAGR (%) 2013-2018 CAGR (%) 2013-2024 4.7 2018-2024 5.3 5.0 Figure 4.15 The Belgian POC Diagnostics Market Forecast: Sales Revenue ($bn) and AGR (%), 2013-2024 Source: Visiongain 2014 4.6.9 The Swiss POC Diagnostics Market Forecast 2014-2024 The Swiss POC diagnostics market is estimated to grow from $0.14bn in 2013 to $0.18bn in 2018, representing a CAGR of 4.1%. Growth between 2018 and 2024 is expected to exhibit a CAGR of 0 1 2 3 4 5 6 7 8 0.00 0.05 0.10 0.15 0.20 0.25 0.30 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales$bn Year Belgium ($bn) AGR (%) Source: Visiongain2014
  • 16. www.visiongain.com Page 143 The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies Table 5.5 Retail Prices of the Blood Glucose Meters and Strips Currently Available in the Market, by Company, 2014 Company Meter Manufacturer's Suggested Retail Price FreeStyle Freedom Lite Meter: $19.99 Strips: $1.46-$1.52/strip FreeStyle InsuLinx Meter: $49.99 Strips: $1.54-$1.60/strip FreeStyle Lite Meter: $19.99 Strips: $1.46-$1.52/strip Precision Xtra Meter: $19.99 Strips: $1.46-$1.52/strip Glucocard 01 Meter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price Glucocard 01-mini Meter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price Glucocard Expression Meter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price Glucocard Vital Meter: Manufacturer declined to provide price Strips: Manufacturer declined to provide price WaveSense Presto Meter: $34.99 Strips: 37¢/strip WaveSense PrestoPro Meter: $38.83 Strips: 37¢/strip Breeze2 Meter: $24.99 Strips: $1.04/strip Contour Meter: $19.99 Strips: $1.24/strip Contour Next Meter: $19.99 Strips: 83¢/strip Contour Next EZ Meter: $19.99 Strips: 83¢/strip Contour Next Link Meter: Sold only w ith pump Strips: 83¢/strip Contour Next USB Meter: $29.99 Strips: 83¢/strip Rightest GE100 Meter: $14.99 Strips: 72¢/strip Rightest GM100 Meter: $9.99-$12.99 Strips: 34¢-50¢/strip Rightest GM300 Meter: $7.99-$10.99 Strips: 26¢-30¢/strip Rightest GM550 Meter: $11.99-$14.99 Strips: 32¢-50¢/strip BioSense Medical Solus V2 Meter: $19.99 Strips: 40¢/strip CVS Blood Glucose Monitor Featuring Truetrack Smart System Meter: $14.99 Strips: 53¢/strip CVS True2go Glucose Test Meter Meter: $9.99 Strips: 70¢/strip CVS Trueresult Blood Glucose Meter: $17.99 Strips: 70¢/strip Diabetic Supply of Suncoast Advocate Redi-Code Plus Speaking Meter Meter: $29.99 Strips: 50¢/strip Entra Health Systems MyGlucoHealth Wireless Meter: $89.95 Strips: 99¢/strip Fifty50 2.0 Meter: $39.95 Strips: 74¢/strip Fifty50 2.0 Sport Meter: $39.95 Strips: 74¢/strip Fora D10 Meter: $79.99 Strips: 80¢/strip Fora D20 Meter: $99.99 Strips: 80¢/strip Fora D30e/f Meter: $149.99 Strips: 80¢/strip Fora D40a/b Meter: $159.99/$199.99 Strips: 80¢/strip Fora G30 Meter: $39.99 Strips: 80¢/strip Fora G31a/b Meter: $84.99/$124.99 Strips: 80¢/strip Fora GD20 Meter: $34.99 Strips: 80¢/strip Fora GD40a/b Meter: $69.99 Strips: 80¢/strip Fora Premium V10 Meter: $49.99 Strips: 80¢/strip Fora V12 Meter: $79.99 Strips: $1.60/strip Fora V30 Meter: $49.99 Strips: 80¢/strip Test N’ Go Meter: $149.99 Strips: $1.20/strip Genesis Health Technologies Genesis Meter Meter: $99.95 Strips: $1.08/strip Bionime Abbott Diabetes Care Arkray AgaMatrix Bayer CVS/ Pharmacy Fora Care Fifty50 Medical Source: Diabetes Forecast 2014; Visiongain 2014
  • 17. www.visiongain.com Page 236 The Point of Care Diagnostics Market Forecast 2014-2024: Future Prospects for Leading Companies Figure 11.8 Siemens Healthcare Revenue Forecast: Revenue ($bn) and AGR (%), 2013- 2024 Source: Visiongain 2014 The outlook in terms of revenue looks promising for Siemens Healthcare in the near future. The “Agenda 2013” initiative set up to increase its regional presence and competitiveness by improving the cost position of the company’s Diagnostics business looks set to streamline its production costs; leading to higher profits. Although Siemens Healthcare’s Diagnostics profit for fiscal 2013 was impacted by an increase in valuation allowances for receivables triggered by a debt rating downgrade related to Greece, the diagnostics sector of the business will see year on year increase in profits from 2014, Visiongain believes. 11.4.3 Siemens Healthcare: POC Diagnostics Product Portfolio Siemens healthcare can be divided in: Healthcare IT & Infrastructure, Hearing Instruments, Laboratory Diagnostics, Medical Imaging and Therapy Systems. Siemens Healthcare Diagnostics provides point-of-care products and services that enable healthcare providers to render better patient management and help ensure optimized clinical outcomes. 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 0 5 10 15 20 25 30 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 AGR(%) Sales$bn Year Siemens Revenue ($bn) AGR (%)